A Single-center, Open-label, One-sequence, Two-treatment Study to Investigate the Effect of ACT-132577 at Steady State on the Pharmacokinetics of Rosuvastatin in Healthy Male Subjects
Latest Information Update: 30 Nov 2022
At a glance
- Drugs Aprocitentan (Primary) ; Rosuvastatin
- Indications Cardiovascular disorders; Hypertension
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals
- 06 Oct 2017 Status changed from recruiting to completed.
- 22 Aug 2017 Status changed from not yet recruiting to recruiting.
- 14 Aug 2017 New trial record